首页 > iHuman研究所 > 师资队伍 > 程建军个人简介
程建军    Research Associate Professor
所在学院 iHuman研究所
研究方向 药物化学
联系方式 chengjj@@shanghaitech.edu.cn
 
  个人简介  
2001.09 – 2005.06,山东大学药学院,药学学士;
2005.09 – 2010.07,中国科学院上海药物研究所,药物化学博士(导师:杨玉社);
2010.07 – 2013.10,上海汇伦生命科技有限公司,高级研究员、部门经理;
2013.11 – 2016.03,美国伊利诺伊大学芝加哥校区,博士后(导师:Alan P. Kozikowski);
2016.03至今,上海科技大学iHuman研究所,Research Associate Professor 、PI。
  主要研究内容  
1. 靶向GPCR的药物发现。针对与人类重大疾病(如肿瘤和中枢神经系统疾病)相关的G蛋白偶联受体(GPCR)开展药物化学研究,设计、合成类药性化合物并进行生物活性研究和成药性评价。
2. 偏向型GPCR配体。针对特定的GPCR受体,设计合成偏向型配体,并进行作用机制研究,探讨GPCR偏向型信号通路的作用特点和结构基础。
  代表性论文  

1. Tan, L; Yan, W.; McCorvy, J. D.;* Cheng, J.* Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential. J Med Chem 2018, 61, 9841−9878.

2. Peng, Y.; McCorvv, J. D.; Harpsoe, K.; Lansu, K.; Yuan, S.; Popov, P.; Qu, L.; Pu, M.; Che, T.; Nikolajsen, L. F.; Huang, X.-P.; Wu, Y.; Shen, L.; Bjorn-Yoshimoto, W. E.; Ding, K.; Wacker, D.; Han, G. W.; Cheng, J.; Katritch, V.; Jensen, A. A.; Hanson, M. A.; Zhao, S.; Gloriam, D. E.; Roth, B. L.;* Stevens, R. C.;* Liu, Z.-J.* 5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology. Cell 2018, 172, 719–730.

3. Pogorelov, V. M.; Rodriguiz, R. M.; Cheng, J.; Huang, M.; Schmerberg, C. M.; Meltzer, H. Y.; Roth, B. L.; Kozikowski, A. P.; Wetsel, W. C.* 5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice. Neuropsychopharmacology 2017, 42, 2163–2177.

4. Zhang, G.; Cheng, J.; McCorvy, J. D.; Lorello, P. J.; Caldarone, B. J.; Roth, B. L.; Kozikowski, A. P.* Discovery of N‑Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications. J Med Chem 2017, 60, 6273−6288.

5. Cheng, J.; McCorvy, J. D.; Giguere, P. M.; Zhu, H.; Kenakin, T.; Roth, B. L.;* Kozikowski, A. P.* Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists. J Med Chem 2016, 59, 9866−9880.

6. Cheng, J.; Giguere, P. M.; Schmerberg, C. M.; Pogorelov, V. M.; Rodriguiz, R. M.; Huang, X.-P.; Zhu, H.; McCorvy, J. D.; Wetsel, W. C.; Roth, B. L.; Kozikowski, A. P.* Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. J Med Chem, 2016, 59, 578–591.

7. Cheng, J.; Kozikowski, A. P.* We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders. ChemMedChem 2015, 10, 1963–1967.

8. Cheng, J.; Giguere, P. M.; Onajole, O. K.; Lv, W.; Gaisin, A.; Gunosewoyo, H.; Schmerberg, C. M.; Pogorelov, V. M.; Rodriguiz, R. M.; Giulio Vistoli, G.; Wetsel, W. C.; Roth, B. L.; Kozikowski, A. P.* Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents. J Med Chem, 2015, 58, 1992–2002.

9. Cheng, J.; Giguere, P. M.; Lv, W.; Roth, B. L.; Kozikowski, A. P.* Design and Synthesis of (2-(5-Chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)cyclopropyl)-methanamine as a Selective Serotonin 2C Agonist. Tetrahedron Lett, 2015, 56, 3420–3422.

10. Cheng, J.;* Qin, J.; Guo, S.; Qiu, H.; Zhong, Y. Design, Synthesis and Evaluation of Novel HDAC Inhibitors as Potential Antitumor Agents. Bioorg Med Chem Lett 2014, 24, 4768–4772.
浏览次数:12529